2016 brought us a near-constant stream of news about SGLT-2 Inhibitors, from their role in combination therapies to their cardiovascular benefits. Here are the ten SGLT-2 items that most engaged you this year.

January:

• Empagliflozin/Linagliptin Combination with Metformin for Triple Therapy

February:

• Empagliflozin Potentially Protects Pancreatic Beta-cells in T1DM
• Shifting Paradigm in Diabetes Treatment – An Interview with Dr. Vinik

April:

• Europe Agrees: Learn the Signs of Atypical DKA in Patients Using SGLT-2s

May:

• AACE/ACE Position Statement On SGLT-2 Inhibitors and DKA Risk

June:

• SGLT-2 Inhibitors in the Spotlight at ADA
• More Good News for Empagliflozin

July:

• Invokana Superior As Second Add-on to Metformin

September: 

• Type I Diabetes Mellitus: A Triple Therapy Approach

October:

• What to Do If Metformin Fails To Get Patients To Target